Overview and Scope
The nasal drug delivery technology refers to administering pharmaceuticals through the nasal cavity to attain therapeutic drug levels in the blood as quickly as possible and the potential for direct drug delivery to the brain via the olfactory neurons. Nasal drug delivery methods circumvent the blood-brain barrier (BBB) and undergo minimal hepatic and intestinal processing.
Sizing and Forecast
The nasal drug delivery technology market size has grown strongly in recent years. It will grow from $77.42 billion in 2023 to $82.98 billion in 2024 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to advancements in drug formulations, increasing prevalence of respiratory disorders, patient preference for non-invasive delivery, expanding geriatric population, regulatory support for nasal drug approvals.
The nasal drug delivery technology market size is expected to see strong growth in the next few years. It will grow to $110.08 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to rise in biologics and peptide therapies, focus on pediatric and geriatric patient needs, partnerships and collaborations in the pharma industry, expansion of over-the-counter (otc) nasal products, increased focus on precision medicine. Major trends in the forecast period include advancements in formulation technology, increased focus on patient-friendly devices, expansion of therapeutic areas, biologics and peptides delivery, innovations in nasal spray technologies.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/nasal-drug-delivery-technology-global-market-report
Segmentation & Regional Insights
The nasal drug delivery technology market covered in this report is segmented –
1) By Dosage Form: Nasal Spray, Nasal Drops, Nasal Gels And Ointments, Nasal Powders, Other Dosage Forms
2) By Container Type: Pressurized Containers, Non-Pressurized Containers
3) By Therapeutic Application: Allergic And Non-Allergic Rhinitis, Nasal Congestion, Asthma, Vaccination, Other Therapeutic Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End User: Home Care Settings, Hospitals
North America was the largest region in the nasal drug delivery technology market in 2023. The regions covered in the nasal drug delivery technology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=10037&type=smp
Major Driver Impacting Market Growth
The increasing incidences of chronic diseases are expected to propel the growth of the nasal drug delivery technology market going forward. Chronic diseases can be defined as conditions that last 1 year or more and require ongoing medical attention, limit activities of daily living, or both. Nasal drug delivery technologies are used for the management of chronic rhinosinusitis to improve the bacterial biofilm or mucociliary clearance due to the complex structure of the nasal cavity through a therapeutic nasal cavity strategy. For instance, in September 2022, according to a report published by the National Institutes of Health (NIH), a US-based biomedical research agency, in 2023, in the United States, the number of people aged 50 and older with at least one chronic illness is predicted to rise by 99.5%, from 71.522 million in 2020 to 142.66 million in 2050. Additionally, the number of people with multimorbidity would rise by 91.16% from 7.8304 million in 2020 to 14.968 million in 2050. Therefore, the increasing incidences of chronic diseases are driving the growth of the market for nasal drug delivery systems.
Key Industry Players
Major companies operating in the nasal drug delivery technology market report are AptarGroup Inc., Becton Dickinson and Company, GlaxoSmithKline PLC, Johnson & Johnson Private Limited, Novartis AG, Pfizer Inc., 3M Company, Cadila Healthcare Limited, Neurelis Inc., OptiNose Inc., Bausch Health Companies Inc., Naveh Pharma Ltd., Teva Pharmaceutical Industries Ltd., Consort Medical PLC, Douglas Pharmaceuticals Ltd., ENT Technologies Pty. Ltd., Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Bayer AG, Abbott Laboratories, Eli Lilly and Company, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Gilead Sciences Inc., Biogen Inc., Roche Holding AG, Allergan PLC, Regeneron Pharmaceuticals Inc., Alexion Pharmaceuticals Inc.
The nasal drug delivery technology market report table of contents includes:
1. Executive Summary
2. Nasal Drug Delivery Technology Market Characteristics
3. Nasal Drug Delivery Technology Market Trends And Strategies
4. Nasal Drug Delivery Technology Market – Macro Economic Scenario
5. Global Nasal Drug Delivery Technology Market Size and Growth
.
.
.
31. Global Nasal Drug Delivery Technology Market Competitive Benchmarking
32. Global Nasal Drug Delivery Technology Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Nasal Drug Delivery Technology Market
34. Nasal Drug Delivery Technology Market Future Outlook and Potential Analysis
35. Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
